Tavilermide is a selective, partial agonist ofTrkA, or a nerve growth factor (NGF) mimetic.

TrkA^[1]

Tavilermide (MIM-D3) is a tyrosine kinase TrkA receptor agonist, which can be used to treat dry eye.Tavilermide is a proteolytically stable, cyclic peptidomimetic that has been shown to be a partial TrkA receptor agonist. Tavilermide demonstrates activities similar to NGF (but does not bind to the p75NTR receptor) and can potentiate the effects of suboptimal concentrations of NGF^[1].

580.54

Solid

C₂₄H₃₂N₆O₁₁

263251-78-1

Room temperature in continental US; may vary elsewhere.

NH4OH : 50 mg/mL(86.13 mM;ultrasonic and adjust pH to 10 with NH4OH)

H₂O : 2 mg/mL(3.45 mM;Need ultrasonic)

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用； 以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

• 1.

  请依序添加每种溶剂： 50%PEG300   50% saline

  Solubility: 25 mg/mL (43.06 mM); Suspended solution; Need ultrasonic
• 2.

  请依序添加每种溶剂： 0.5%CMC-Na/saline water

  Solubility: 10 mg/mL (17.23 mM); Suspended solution; Need ultrasonic
• 3.

  请依序添加每种溶剂： PBS

  Solubility: 4.17 mg/mL (7.18 mM); Clear solution; Need ultrasonic and warming and heat to 60℃